TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gradual vs. Abrupt Cessation Treatment for Smoking
Brief Summary: This study tests whether stopping smoking by gradually cutting down first is more or less successful than stopping abruptly. We hypothesize that stopping by gradually cutting down first will produce more abstinence than stopping abruptly.


Options:
A: Arm Label: Gradual reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction Phone Counseling, Drug: Pre-Quit Nicotine Lozenges, Drug: Post-Quit Nicotine Lozenges | Arm Label: Abrupt cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Abrupt Phone Counseling, Drug: Post-Quit Nicotine Lozenges | Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal Abrupt Phone Counseling, Drug: Post-Quit Nicotine Lozenges | Intervention Type: BEHAVIORAL; Name: Reduction Phone Counseling; Assigned to Arm(s): Gradual reduction | Intervention Type: BEHAVIORAL; Name: Abrupt Phone Counseling; Assigned to Arm(s): Abrupt cessation | Intervention Type: BEHAVIORAL; Name: Minimal Abrupt Phone Counseling; Assigned to Arm(s): Minimal intervention | Intervention Type: DRUG; Name: Pre-Quit Nicotine Lozenges; Assigned to Arm(s): Gradual reduction | Intervention Type: DRUG; Name: Post-Quit Nicotine Lozenges; Assigned to Arm(s): Abrupt cessation, Gradual reduction, Minimal intervention
B: Intervention Type: BEHAVIORAL; Name: Self-Help Intervention Program-High Blood Pressure; Assigned to Arm(s): N/A
C: Arm Label: Usual Care Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Step Up Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Step Up Wellness Program | Intervention Type: BEHAVIORAL; Name: Step Up Wellness Program; Assigned to Arm(s): Step Up Intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care Control
D: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline Service + 10 automated monitoring calls | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline service + 20 automated monitoring calls | Intervention Type: BEHAVIORAL; Name: Quitline Service + 10 automated monitoring calls; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Quitline service + 20 automated monitoring calls; Assigned to Arm(s): Group C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gradual vs. Abrupt Cessation Treatment for Smoking
Brief Summary: This study tests whether stopping smoking by gradually cutting down first is more or less successful than stopping abruptly. We hypothesize that stopping by gradually cutting down first will produce more abstinence than stopping abruptly.


Options:
A: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A
B: Arm Label: Smoking reduction intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking reduction intervention | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and diet advice control | Intervention Type: BEHAVIORAL; Name: Smoking reduction intervention; Assigned to Arm(s): Smoking reduction intervention arm | Intervention Type: BEHAVIORAL; Name: Exercise and diet advice control; Assigned to Arm(s): Control arm
C: Arm Label: Less Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: More Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Less Dependent Smokers, More Dependent Smokers
D: Arm Label: Gradual reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction Phone Counseling, Drug: Pre-Quit Nicotine Lozenges, Drug: Post-Quit Nicotine Lozenges | Arm Label: Abrupt cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Abrupt Phone Counseling, Drug: Post-Quit Nicotine Lozenges | Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal Abrupt Phone Counseling, Drug: Post-Quit Nicotine Lozenges | Intervention Type: BEHAVIORAL; Name: Reduction Phone Counseling; Assigned to Arm(s): Gradual reduction | Intervention Type: BEHAVIORAL; Name: Abrupt Phone Counseling; Assigned to Arm(s): Abrupt cessation | Intervention Type: BEHAVIORAL; Name: Minimal Abrupt Phone Counseling; Assigned to Arm(s): Minimal intervention | Intervention Type: DRUG; Name: Pre-Quit Nicotine Lozenges; Assigned to Arm(s): Gradual reduction | Intervention Type: DRUG; Name: Post-Quit Nicotine Lozenges; Assigned to Arm(s): Abrupt cessation, Gradual reduction, Minimal intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gradual vs. Abrupt Cessation Treatment for Smoking
Brief Summary: This study tests whether stopping smoking by gradually cutting down first is more or less successful than stopping abruptly. We hypothesize that stopping by gradually cutting down first will produce more abstinence than stopping abruptly.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Gradual reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction Phone Counseling, Drug: Pre-Quit Nicotine Lozenges, Drug: Post-Quit Nicotine Lozenges | Arm Label: Abrupt cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Abrupt Phone Counseling, Drug: Post-Quit Nicotine Lozenges | Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal Abrupt Phone Counseling, Drug: Post-Quit Nicotine Lozenges | Intervention Type: BEHAVIORAL; Name: Reduction Phone Counseling; Assigned to Arm(s): Gradual reduction | Intervention Type: BEHAVIORAL; Name: Abrupt Phone Counseling; Assigned to Arm(s): Abrupt cessation | Intervention Type: BEHAVIORAL; Name: Minimal Abrupt Phone Counseling; Assigned to Arm(s): Minimal intervention | Intervention Type: DRUG; Name: Pre-Quit Nicotine Lozenges; Assigned to Arm(s): Gradual reduction | Intervention Type: DRUG; Name: Post-Quit Nicotine Lozenges; Assigned to Arm(s): Abrupt cessation, Gradual reduction, Minimal intervention
C: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
D: Intervention Type: DRUG; Name: zyban; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.
Brief Summary: The aim of the study will be to investigate the effect of certolizumab pegol on the intestinal mucosa in active Crohn's disease.


Options:
A: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
C: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg
D: Arm Label: Active 1; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol, Other: Placebo | Arm Label: Active 2; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Active 1 | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Active 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Active 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.
Brief Summary: The aim of the study will be to investigate the effect of certolizumab pegol on the intestinal mucosa in active Crohn's disease.


Options:
A: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
B: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg
C: Arm Label: Double Blind; Type: PLACEBO_COMPARATOR; Interventions: Biological: adalimumab, Biological: placebo | Arm Label: Open Label; Type: OTHER; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Open Label
D: Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Open Label; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 1: Open Label

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clarithromycin as Immunomodulatory Therapy for the Management of Septic Syndrome by Ventilator-Associated Pneumonia
Brief Summary: The aim of this clinical trial is to clarify the clinical efficacy of clarithromycin as immunotherapy for the management of septic syndrome by ventilator-associated pneumonia.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Azithromycin and Placebo | Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin and Placebo | Intervention Type: DRUG; Name: Azithromycin and Placebo; Assigned to Arm(s): Azithromycin, Placebo
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin 250 mg tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: azithromycin 250 mg tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): Placebo
C: Arm Label: Physiologic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Erythromycine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Physiologic saline | Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): Erythromycine
D: Intervention Type: DRUG; Name: Intravenous Clarithromycin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementing Tobacco Control in Dental Practice
Brief Summary: Our goal is to test a dentist-hygienist team intervention to help dental patients quit smoking and determine if it can be effectively and cost-effectively implemented and sustained.

Staff in half of the HMO's 14 large dental facilities will be trained to provide brief cessation advice and assistance and to encourage smokers to talk by phone with a tobacco counselor before they leave the dental office. Phone counselors will provide brief counseling, assess stage, and offer a full list of cessation services. The Active Referral intervention strategy is both practical and innovative, as it takes advantage of available resources; efficiently distributes intervention activities between dentists, hygienists, and counseling specialists; and could be delivered in individual, small, or large dental practices. This intervention is provided as part of routine care to all patients seen for annual dental and periodontal exams.Consented patients will receive a short phone survey shortly after the exam to assess smoking status, satisfaction with delivery of support services,and satisfaction with intervention. Consented patients in treatment and control facilities will be surveyed by phone at one year to re-assess smoking status and satisfaction with services.


Options:
A: Intervention Type: BEHAVIORAL; Name: Active referral; Assigned to Arm(s): N/A
B: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Rectal Cancer.
Brief Summary: COLOR II is a randomized, international, multi center study comparing the outcomes of laparoscopic and conventional resection of rectal carcinoma below 15 cm with curative intent. Clinical and operative data will be collected centrally in the coordinating centre in Halifax, Canada. Quality of life and costs will be assessed on a national basis.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Procedure: surgery | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): 1
B: Intervention Type: PROCEDURE; Name: Laparoscopic surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Conventional surgery; Assigned to Arm(s): N/A
C: Arm Label: OPEN SURGERY; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RECTAL CANCER RESECTION | Arm Label: LAPAROSCOPIC SURGERY; Type: EXPERIMENTAL; Interventions: Procedure: RECTAL CANCER RESECTION | Intervention Type: PROCEDURE; Name: RECTAL CANCER RESECTION; Assigned to Arm(s): LAPAROSCOPIC SURGERY, OPEN SURGERY
D: Arm Label: open rectal resection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: open rectal resection | Arm Label: laparoscopic rectal resection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic rectal resection | Intervention Type: PROCEDURE; Name: open rectal resection; Assigned to Arm(s): open rectal resection | Intervention Type: PROCEDURE; Name: laparoscopic rectal resection; Assigned to Arm(s): laparoscopic rectal resection

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Rectal Cancer.
Brief Summary: COLOR II is a randomized, international, multi center study comparing the outcomes of laparoscopic and conventional resection of rectal carcinoma below 15 cm with curative intent. Clinical and operative data will be collected centrally in the coordinating centre in Halifax, Canada. Quality of life and costs will be assessed on a national basis.


Options:
A: Arm Label: Chemoradiotherapy+TEM; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine (Xeloda), Radiation: 50.4 Gy, Procedure: Transanal Endoscopic Microsurgery | Arm Label: Total Mesorectal Excision; Type: OTHER; Interventions: Procedure: Total Mesorectal Excision | Intervention Type: DRUG; Name: Capecitabine (Xeloda); Assigned to Arm(s): Chemoradiotherapy+TEM | Intervention Type: RADIATION; Name: 50.4 Gy; Assigned to Arm(s): Chemoradiotherapy+TEM | Intervention Type: PROCEDURE; Name: Transanal Endoscopic Microsurgery; Assigned to Arm(s): Chemoradiotherapy+TEM | Intervention Type: PROCEDURE; Name: Total Mesorectal Excision; Assigned to Arm(s): Total Mesorectal Excision
B: Arm Label: 1; Type: OTHER; Interventions: Procedure: surgery | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): 1
C: Arm Label: Treatment (capecitabine, oxaliplatin, radiotherapy, surgery); Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: oxaliplatin, Procedure: neoadjuvant therapy, Radiation: radiation therapy | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Treatment (capecitabine, oxaliplatin, radiotherapy, surgery) | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): Treatment (capecitabine, oxaliplatin, radiotherapy, surgery) | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): Treatment (capecitabine, oxaliplatin, radiotherapy, surgery) | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Treatment (capecitabine, oxaliplatin, radiotherapy, surgery)
D: Arm Label: Total Mesorectal Excision; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Additional TME surgery | Arm Label: Adjuvant chemoradiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Adjuvant chemoradiotherapy, Drug: capecitabine | Intervention Type: RADIATION; Name: Adjuvant chemoradiotherapy; Assigned to Arm(s): Adjuvant chemoradiotherapy | Intervention Type: PROCEDURE; Name: Additional TME surgery; Assigned to Arm(s): Total Mesorectal Excision | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Adjuvant chemoradiotherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder
Brief Summary: This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of quetiapine.


Options:
A: Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A
B: Arm Label: 600 mg/day quetiapine (Group B); Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: 1200 mg/day quetiapine (Group A); Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): 1200 mg/day quetiapine (Group A) | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): 600 mg/day quetiapine (Group B)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 3
D: Arm Label: Lurasidone Open-Label Arm A; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm C; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Intervention Type: DRUG; Name: Lurasidone HCl; Assigned to Arm(s): Lurasidone Open-Label Arm A, Lurasidone Open-Label Arm B, Lurasidone Open-Label Arm C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy
Brief Summary: The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).


Options:
A: Arm Label: Lepicol probiotic & prebiotic formula+simple lifestyle advice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepicol probiotic & prebiotic formula, Other: Simple lifestyle advice | Arm Label: Simple lifestyle advice alone; Type: PLACEBO_COMPARATOR; Interventions: Other: Simple lifestyle advice | Intervention Type: DRUG; Name: Lepicol probiotic & prebiotic formula; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice | Intervention Type: OTHER; Name: Simple lifestyle advice; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice, Simple lifestyle advice alone
B: Arm Label: Rifaximin; Type: EXPERIMENTAL; Interventions: Drug: Rifaximin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rifaximin; Assigned to Arm(s): Rifaximin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: synbiotic | Arm Label: maltodexterin; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): maltodexterin
D: Arm Label: alcohol, hepatitis, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: alcohol, hepatitis, Placebo | Arm Label: hepatitis, alcohol, probiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: hepatitis, alcohol, probiotics | Intervention Type: DRUG; Name: hepatitis, alcohol, probiotics; Assigned to Arm(s): hepatitis, alcohol, probiotics | Intervention Type: DRUG; Name: alcohol, hepatitis, Placebo; Assigned to Arm(s): alcohol, hepatitis, Placebo

Answer: B